A novel series of antagonists of the human P2X7 receptor is described. Modification of substituents enabled identification of compounds selective for the rat P2X7 receptor and provides useful pharmacological tools for evaluation of the role of P2X7 in disease.
Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X(7) Receptor Antagonists/Interleukin-1beta Inhibitors. Publishing Authors By Initials
Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X(7) Receptor Antagonists/Interleukin-1beta Inhibitors. Journal Published:
PUBLICATION TYPE: Journal Article
Journal: Journal of medicinal chemistry
VOLUME: 50
Page Numbers: 5882-5
Journal Abbreviation: J. Med. Chem.
ISSN: 0022-2623
DAY: 27
MONTH: 10
YEAR: 2007
Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X(7) Receptor Antagonists/Interleukin-1beta Inhibitors. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 9716531
Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X(7) Receptor Antagonists/Interleukin-1beta Inhibitors. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X(7) Receptor Antagonists/Interleukin-1beta Inhibitors. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X(7) Receptor Antagonists/Interleukin-1beta Inhibitors.
AFFILIATION: Departments of Medicinal Chemistry, Discovery Bioscience, and Physical and Metabolic Science, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leics LE11 5RH, U.K.
Country: United States
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: J Med Chem
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X7 Receptor Antagonists/Interleukin-1beta Inhibitors Related Publications